Clinical Trial Update: TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for TREXIMA and RELPAX evaluating gastric scintigraphy in migraine disorders; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine Disorders

Drugs mentioned

• RELPAX (Eletriptan hydrobromide)
• Trexima (sumatriptan/naproxen)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Migraine Disorders | Phase 3 | Status: COMPLETED | Results posted: 2018-02-12